Cargando…

Antibodies directed against endogenous and exogenous citrullinated antigens pre-date the onset of rheumatoid arthritis

BACKGROUND: Anti-citrullinated-peptide antibodies (ACPA) have been detected in individuals with developing rheumatoid arthritis (RA) before the onset of symptom, with an initially limited spectrum of reactivities that gradually broadens. The aim was to analyze the evolution of ACPA response pre-dati...

Descripción completa

Detalles Bibliográficos
Autores principales: Johansson, Linda, Pratesi, Federico, Brink, Mikael, Ärlestig, Lisbeth, D’Amato, Claudia, Bartaloni, Debora, Migliorini, Paola, Rantapää-Dahlqvist, Solbritt
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4891920/
https://www.ncbi.nlm.nih.gov/pubmed/27255888
http://dx.doi.org/10.1186/s13075-016-1031-0
_version_ 1782435349073494016
author Johansson, Linda
Pratesi, Federico
Brink, Mikael
Ärlestig, Lisbeth
D’Amato, Claudia
Bartaloni, Debora
Migliorini, Paola
Rantapää-Dahlqvist, Solbritt
author_facet Johansson, Linda
Pratesi, Federico
Brink, Mikael
Ärlestig, Lisbeth
D’Amato, Claudia
Bartaloni, Debora
Migliorini, Paola
Rantapää-Dahlqvist, Solbritt
author_sort Johansson, Linda
collection PubMed
description BACKGROUND: Anti-citrullinated-peptide antibodies (ACPA) have been detected in individuals with developing rheumatoid arthritis (RA) before the onset of symptom, with an initially limited spectrum of reactivities that gradually broadens. The aim was to analyze the evolution of ACPA response pre-dating symptom onset, using four selected citrullinated exogenous and endogenous antigens. METHODS: A cohort of 521 individuals sampled before symptoms of RA appeared and 272 population controls were identified from the Biobank of Northern Sweden; 241 samples from patients with early RA were also collected. ACPA were detected by ELISA on viral citrullinated peptides (VCP) derived from Epstein-Barr-virus nuclear antigen (EBNA)1 and EBNA2 (VCP1 and VCP2) and histone-4-derived citrullinated peptides (HCP1 and HCP2). RESULTS: In pre-symptomatic individuals vs. patients with early RA, anti-VCP1 antibodies were detected in 10.4 % vs. 36.1 %, anti-VCP2 in 17.1 % vs. 52.3 %, anti-HCP1 in 10.2 % vs. 37.3 %, and anti-HCP2 in 16.3 % vs. 48.5 %, respectively. Anti-VCP and anti-HCP concentrations were significantly increased in pre-symptomatic individuals vs. controls (p < 0.001) and were increased approaching symptom onset. Anti-VCP and anti-HCP appeared simultaneously (median (IQR) 5.3 (6) years before symptom onset) and in combination yielded a high-risk ratio for disease development (OR = 8.0–18.9). Anti-VCP2 and anti-HCP2 antibodies were associated with HLA-DRB1*0401 in pre-symptomatic individuals. Three peptidylarginine deiminase (PAD)I3/PADI4 single nucleotide polymorphisms (SNPs) were significantly associated with anti-HCP1. CONCLUSIONS: Anti-VCP and anti-HCP antibodies pre-date symptom onset and predict disease development, but no hierarchy of citrullinated epitopes can be identified. These results suggest that no inciting citrullinated antigen so far described is common to all patients with RA. The association between PADI3/PADI4 polymorphism and anti-HCP1 antibodies suggests a novel link between deimination and production of ACPA. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s13075-016-1031-0) contains supplementary material, which is available to authorized users.
format Online
Article
Text
id pubmed-4891920
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-48919202016-06-04 Antibodies directed against endogenous and exogenous citrullinated antigens pre-date the onset of rheumatoid arthritis Johansson, Linda Pratesi, Federico Brink, Mikael Ärlestig, Lisbeth D’Amato, Claudia Bartaloni, Debora Migliorini, Paola Rantapää-Dahlqvist, Solbritt Arthritis Res Ther Research Article BACKGROUND: Anti-citrullinated-peptide antibodies (ACPA) have been detected in individuals with developing rheumatoid arthritis (RA) before the onset of symptom, with an initially limited spectrum of reactivities that gradually broadens. The aim was to analyze the evolution of ACPA response pre-dating symptom onset, using four selected citrullinated exogenous and endogenous antigens. METHODS: A cohort of 521 individuals sampled before symptoms of RA appeared and 272 population controls were identified from the Biobank of Northern Sweden; 241 samples from patients with early RA were also collected. ACPA were detected by ELISA on viral citrullinated peptides (VCP) derived from Epstein-Barr-virus nuclear antigen (EBNA)1 and EBNA2 (VCP1 and VCP2) and histone-4-derived citrullinated peptides (HCP1 and HCP2). RESULTS: In pre-symptomatic individuals vs. patients with early RA, anti-VCP1 antibodies were detected in 10.4 % vs. 36.1 %, anti-VCP2 in 17.1 % vs. 52.3 %, anti-HCP1 in 10.2 % vs. 37.3 %, and anti-HCP2 in 16.3 % vs. 48.5 %, respectively. Anti-VCP and anti-HCP concentrations were significantly increased in pre-symptomatic individuals vs. controls (p < 0.001) and were increased approaching symptom onset. Anti-VCP and anti-HCP appeared simultaneously (median (IQR) 5.3 (6) years before symptom onset) and in combination yielded a high-risk ratio for disease development (OR = 8.0–18.9). Anti-VCP2 and anti-HCP2 antibodies were associated with HLA-DRB1*0401 in pre-symptomatic individuals. Three peptidylarginine deiminase (PAD)I3/PADI4 single nucleotide polymorphisms (SNPs) were significantly associated with anti-HCP1. CONCLUSIONS: Anti-VCP and anti-HCP antibodies pre-date symptom onset and predict disease development, but no hierarchy of citrullinated epitopes can be identified. These results suggest that no inciting citrullinated antigen so far described is common to all patients with RA. The association between PADI3/PADI4 polymorphism and anti-HCP1 antibodies suggests a novel link between deimination and production of ACPA. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s13075-016-1031-0) contains supplementary material, which is available to authorized users. BioMed Central 2016-06-03 2016 /pmc/articles/PMC4891920/ /pubmed/27255888 http://dx.doi.org/10.1186/s13075-016-1031-0 Text en © The Author(s). 2016 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research Article
Johansson, Linda
Pratesi, Federico
Brink, Mikael
Ärlestig, Lisbeth
D’Amato, Claudia
Bartaloni, Debora
Migliorini, Paola
Rantapää-Dahlqvist, Solbritt
Antibodies directed against endogenous and exogenous citrullinated antigens pre-date the onset of rheumatoid arthritis
title Antibodies directed against endogenous and exogenous citrullinated antigens pre-date the onset of rheumatoid arthritis
title_full Antibodies directed against endogenous and exogenous citrullinated antigens pre-date the onset of rheumatoid arthritis
title_fullStr Antibodies directed against endogenous and exogenous citrullinated antigens pre-date the onset of rheumatoid arthritis
title_full_unstemmed Antibodies directed against endogenous and exogenous citrullinated antigens pre-date the onset of rheumatoid arthritis
title_short Antibodies directed against endogenous and exogenous citrullinated antigens pre-date the onset of rheumatoid arthritis
title_sort antibodies directed against endogenous and exogenous citrullinated antigens pre-date the onset of rheumatoid arthritis
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4891920/
https://www.ncbi.nlm.nih.gov/pubmed/27255888
http://dx.doi.org/10.1186/s13075-016-1031-0
work_keys_str_mv AT johanssonlinda antibodiesdirectedagainstendogenousandexogenouscitrullinatedantigenspredatetheonsetofrheumatoidarthritis
AT pratesifederico antibodiesdirectedagainstendogenousandexogenouscitrullinatedantigenspredatetheonsetofrheumatoidarthritis
AT brinkmikael antibodiesdirectedagainstendogenousandexogenouscitrullinatedantigenspredatetheonsetofrheumatoidarthritis
AT arlestiglisbeth antibodiesdirectedagainstendogenousandexogenouscitrullinatedantigenspredatetheonsetofrheumatoidarthritis
AT damatoclaudia antibodiesdirectedagainstendogenousandexogenouscitrullinatedantigenspredatetheonsetofrheumatoidarthritis
AT bartalonidebora antibodiesdirectedagainstendogenousandexogenouscitrullinatedantigenspredatetheonsetofrheumatoidarthritis
AT migliorinipaola antibodiesdirectedagainstendogenousandexogenouscitrullinatedantigenspredatetheonsetofrheumatoidarthritis
AT rantapaadahlqvistsolbritt antibodiesdirectedagainstendogenousandexogenouscitrullinatedantigenspredatetheonsetofrheumatoidarthritis